F-18-PSMA-1007 not checked

ABX advanced biochemical compounds GmbH

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.”In the company’s words, NCT04102553 on ClinicalTrials.gov
Tested for
Prostate Cancer, Prostate Cancer Recurrent
Main trialPhase 3
“This study evaluates the diagnostic performance and safety of F-18-PSMA-1007 and F-18-Fluorocholine PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.”In the company’s words, NCT04102553 on ClinicalTrials.gov

Other drugs for Prostate Cancer

All 194 drugs for Prostate Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Completed 30 Oct 2020 F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow F-18-PSMA-1007

Following is part of Solo: you see every change to F-18-PSMA-1007 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in